Trials / No Longer Available
No Longer AvailableNCT00994916
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- David Lacomis, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).
Detailed description
Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll if they are medically stable. They may receive 3,4 diaminopyridine in addition to other treatments and standard of care investigations for LEMS under supervision of the primary investigator. Safety laboratory studies and EKGs will be obtained. The study has been approved by the University of Pittsburgh IRB. There is a local Data-Safety Monitoring Board. The investigator has a hold on enrolling new subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3,4 diaminopyridine | 3,4 diaminopyridine up to 80 mg daily in divided doses |
Timeline
- First posted
- 2009-10-14
- Last updated
- 2019-07-09
Source: ClinicalTrials.gov record NCT00994916. Inclusion in this directory is not an endorsement.